- Home
- ECOR vs SONN Comparison
ECOR vs SONN Comparison
Compare ECOR & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- SONN
- Stock Information
- Founded
- ECOR 2005
- SONN N/A
- Country
- ECOR United States
- SONN United States
- Employees
- ECOR N/A
- SONN N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- SONN Health Care
- Exchange
- ECOR Nasdaq
- SONN Nasdaq
- Market Cap
- ECOR 39.6M
- SONN 32.4M
- IPO Year
- ECOR 2018
- SONN N/A
- Fundamental
- Price
- ECOR $4.97
- SONN $4.02
- Analyst Decision
- ECOR Strong Buy
- SONN Strong Buy
- Analyst Count
- ECOR 2
- SONN 1
- Target Price
- ECOR $25.50
- SONN $20.00
- AVG Volume (30 Days)
- ECOR 78.5K
- SONN 773.9K
- Earning Date
- ECOR 11-05-2025
- SONN 12-16-2025
- Dividend Yield
- ECOR N/A
- SONN N/A
- EPS Growth
- ECOR N/A
- SONN N/A
- EPS
- ECOR N/A
- SONN N/A
- Revenue
- ECOR $29,835,000.00
- SONN $1,000,000.00
- Revenue This Year
- ECOR $24.55
- SONN $5,376.22
- Revenue Next Year
- ECOR $41.13
- SONN N/A
- P/E Ratio
- ECOR N/A
- SONN N/A
- Revenue Growth
- ECOR 27.90
- SONN 1689.52
- 52 Week Low
- ECOR $4.16
- SONN $1.08
- 52 Week High
- ECOR $19.49
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- ECOR 44.55
- SONN 44.01
- Support Level
- ECOR $4.53
- SONN $3.95
- Resistance Level
- ECOR $4.98
- SONN $5.06
- Average True Range (ATR)
- ECOR 0.40
- SONN 0.87
- MACD
- ECOR -0.09
- SONN -0.08
- Stochastic Oscillator
- ECOR 17.74
- SONN 18.83
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.